Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

MT Newswires Live07-27

Yarrow Bioscience (YARW) said Monday that it has completed its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200 million.

The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.

The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.

Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.

Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.

The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' disease, with or without concurrent thyroid eye disease. Phase 2a data are expected in the second half of 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654043338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654043338","market":"sh","top_or_hot":-1,"title":"Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101","media":"MT Newswires Live","content":"<html><body><p> Yarrow Bioscience (YARW) said Monday that it has completed its merger with VYNE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and the previously announced private financings totaling approximately $200 million.</p><p>The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.</p><p>The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.</p><p>Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.</p><p>Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.</p><p>The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' disease, with or without concurrent thyroid eye disease. Phase 2a data are expected in the second half of 2027.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-27 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Yarrow Bioscience (YARW) said Monday that it has completed its merger with VYNE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and the previously announced private financings totaling approximately $200 million.</p><p>The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.</p><p>The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.</p><p>Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.</p><p>Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.</p><p>The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' disease, with or without concurrent thyroid eye disease. Phase 2a data are expected in the second half of 2027.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4173","symbol_name":"保险经纪商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654043338","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654043338","pubTimestamp":1785158242,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Yarrow Bioscience  said Monday that it has completed its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200 million.The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' dis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4173":"保险经纪商","YARW":"YARROW BIOSCIENCE, INC.","YB":"元保","BK4007":"制药"},"translate_title":"Yarrow Bioscience 完成 VYNE Therapeutics 合并，开始 YB-101 的 2 期试验给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VYNE":1.5,"YARW":1.5,"YB":1.5},"content_text":"Yarrow Bioscience (YARW) said Monday that it has completed its merger with VYNE Therapeutics and the previously announced private financings totaling approximately $200 million.The combined company will operate as Yarrow Bioscience and its shares are expected to begin trading on the Nasdaq Capital Market on Tuesday under the ticker symbol YARW.The combined company will be led by President and Chief Executive Officer Rebecca Frey, Chief Operating Officer Rachael Alford, and Chief Financial Officer Tyler Zeronda.Bill Lundberg, former chief executive of biotech firm Merus, will become chairman of the board of directors.Yarrow said its lead product candidate, YB-101, is a potential first-in-class anti-thyroid-stimulating hormone receptor monoclonal antibody designed to directly disrupt the central mechanism driving both Graves' disease and thyroid eye disease in a single targeted treatment.The company also said it has initiated dosing in a Phase 2a/2b trial of YB-101 in patients with Graves' disease, with or without concurrent thyroid eye disease. Phase 2a data are expected in the second half of 2027.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654043338","isCrawlerRequest":true}